Fluvoxamine Extended-release Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Fluvoxamine Extended-release Indications
Indications
Fluvoxamine Extended-release Dosage and Administration
Adult
Children
Fluvoxamine Extended-release Contraindications
Contraindications
Fluvoxamine Extended-release Boxed Warnings
Boxed Warning
Fluvoxamine Extended-release Warnings/Precautions
Warnings/Precautions
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. History of seizures (discontinue if occurs), mania/hypomania. ECT. Cardiovascular disease. Liver dysfunction. Risk for bleeding events. Angle-closure glaucoma. Conditions that affect metabolism or hemodynamic response. Hyponatremia (esp. in elderly). Sexual dysfunction. Reduced activity of CYP2D6. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (esp. during 3rd trimester). Nursing mothers: monitor infants.
Fluvoxamine Extended-release Pharmacokinetics
See Literature
Fluvoxamine Extended-release Interactions
Interactions
See Contraindications. Prolongation of QT interval with pimozide, thioridazine. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue); monitor. Potentiates diazepam (not recommended), triazolam and alprazolam (reduce their doses by at least ½), midazolam, theophylline (reduce its dose by ⅔ and monitor), warfarin, carbamazepine, tricyclic antidepressants (reduce their doses and monitor), propranolol, metoprolol (reduce their doses), clozapine, methadone, tacrine. Caution with drugs that inhibit CYP2D6 (eg, quinidine) or CYP3A4, phenytoin, diltiazem. Increased risk of bleeding with concomitant NSAIDs, aspirin, warfarin, and others that affect coagulation. Monitor mexiletine levels. Smokers may have increased metabolism.
Fluvoxamine Extended-release Adverse Reactions
Adverse Reactions
Fluvoxamine Extended-release Clinical Trials
See Literature
Fluvoxamine Extended-release Note
Notes
Fluvoxamine Extended-release Patient Counseling
See Literature